Interestingly, evidence from other research suggests that first-line pembrolizumab monotherapy response in patients with NSCLC and a PD-L1 TPS ≥50% tends to be poor in patients with elevated baseline CRP levels [38]. Here, CD274 is linked to non-small cell lung carcinoma.